In silico repositioning of approved drugs against Schistosoma mansoni energy metabolism targets.

Schistosomiasis is a neglected parasitosis caused by Schistosoma spp. Praziquantel is used for the chemoprophylaxis and treatment of this disease. Although this monotherapy is effective, the risk of resistance and its low efficiency against immature worms compromises its effectiveness. Therefore, it is necessary to develop new schistosomicide drugs. However, the development of new drugs is a long and expensive process. The repositioning of approved drugs has been proposed as a quick, cheap, and effective alternative to solve this problem. This study employs chemogenomic analysis with use of bioinformatics tools to search, identify, and analyze data on approved drugs with the potential to inhibit Schistosoma mansoni energy metabolism enzymes. The TDR Targets Database, Gene DB, Protein, DrugBank, Therapeutic Targets Database (TTD), Promiscuous, and PubMed databases were used. Fifty-nine target proteins were identified, of which 18 had one or more approved drugs. The results identified 20 potential drugs for schistosomiasis treatment; all approved for use in humans.

Extended-spectrum ß-lactamases producing Klebsiella pneumoniae isolated in two hospitals in Goiânia/Brazil: detection, prevalence, antimicrobial susceptibility and molecular typing.

This study was developed to evaluate the prevalence of extended-spectrum ß-lactamases (ESBL) producing Klebsiella pneumoniae in two hospitals (A and B) in Goiânia, GO, Brazil. The antimicrobial susceptibility of the isolates was determined using the MicroScan WalkAway (Dade Behring, USA). Tests to evaluate the genetic correlation between the isolates were also performed. For the ESBL phenotypic test, the Double-disk diffusion (DD) method was used. The strains isolated in Hospital B were submitted to DNA analysis by pulsed-field gel electrophoresis (PFGE). The study showed high prevalence of ESBL-producing K. pneumoniae (25% in hospital A and 66.7% in hospital B), with high rates of antimicrobial resistance. The most active compound was imipenem (100% susceptibility in vitro). The PFGE test showed similiarity in five strains and variability in six strains.The high prevalence of ESBL-producing Klebsiella may be due to individual selection and to dissemination of a common strain.